TRIHEXYPHENIDYL

Details

Stereochemistry	RACEMIC
Molecular Formula	C20H31NO
Molecular Weight	301.4662
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(CCN1CCCCC1)(C2CCCCC2)C3=CC=CC=C3

InChI

InChIKey=HWHLPVGTWGOCJO-UHFFFAOYSA-N

InChI=1S/C20H31NO/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21/h1,4-5,10-11,19,22H,2-3,6-9,12-17H2

HIDE SMILES / InChI

Molecular Formula	C20H31NO
Molecular Weight	301.4662
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.drugbank.ca/drugs/DB00376
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/006773_s036_artane.pdf

Trihexyphenidyl (Artane, Apo-Trihex, Parkin, Pacitane), also known as benzhexol and trihex has been in clinical usage for decades.It is an anticholinergic used in the symptomatic treatment of all etiologic groups of parkinsonism and drug induced extrapyramidal reactions (except tardive dyskinesia). Trihexyphenidyl possesses both anticholinergic and antihistaminic effects, although only the former has been established as therapeutically significant in the management of parkinsonism. Trihexyphenidyl is a selective M1 muscarinic acetylcholine receptor antagonist. It is able to discriminate between the M1 (cortical or neuronal) and the peripheral muscarinic subtypes (cardiac and glandular). Trihexyphenidyl partially blocks cholinergic activity in the CNS, which is responsible for the symptoms of Parkinson's disease. It is also thought to increase the availability of dopamine, a brain chemical that is critical in the initiation and smooth control of voluntary muscle movement. Trihexyphenidyl is indicated for the treatment of parkinson's disease and extrapyramidal reactions caused by drugs.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Muscarinic acetylcholine receptor M1 168 Target ID: CHEMBL216 Sources: http://www.drugbank.ca/drugs/DB00376	Antagonist 2849	1.3 nM [IC50]
Muscarinic acetylcholine receptor M4 87 Target ID: CHEMBL1821 Sources: http://www.drugbank.ca/drugs/DB00376 \| http://www.genome.jp/dbget-bin/www_bget?D00787	Antagonist 2849	6.7 nM [IC50]
Muscarinic acetylcholine receptor M5 63 Target ID: CHEMBL2035 Sources: http://www.drugbank.ca/drugs/DB00376 \| http://www.genome.jp/dbget-bin/www_bget?D00787	Antagonist 2849	10.3 nM [IC50]
Muscarinic acetylcholine receptor M3 160 Target ID: CHEMBL245 Sources: http://www.drugbank.ca/drugs/DB00376 \| http://www.genome.jp/dbget-bin/www_bget?D00787	Antagonist 2849	26.3 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Parkinson's disease 232 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/006773_s036_artane.pdf	Primary		Approved 8583	Trihexyphenidyl hydrochloride Approved Use Trihexyphenidyl HCl tablets are indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones. Launch Date 1949
Extrapyramidal disorders caused by central nervous system drugs 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/006773_s036_artane.pdf	Secondary		Approved 8583	Trihexyphenidyl hydrochloride Approved Use Trihexyphenidyl HCl tablets are indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones. Launch Date 1949

C_max

Value	Dose	Co-administered	Analyte	Population
24.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3225767/	5 mg 2 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TRIHEXYPHENIDYL serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
14.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3225767/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		TRIHEXYPHENIDYL serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
334 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3225767/	5 mg 2 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TRIHEXYPHENIDYL serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
294 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3225767/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		TRIHEXYPHENIDYL serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
8.67 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3225767/	5 mg 2 times / day multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TRIHEXYPHENIDYL serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3225767/	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:		TRIHEXYPHENIDYL serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
0.55 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 0.55 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.55 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21310336/	unhealthy, 1-18 years Health Status: unhealthy Age Group: 1-18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21310336/	Disc. AE: Constipation, Gastrointestinal disorders... AEs leading to discontinuation/dose reduction: Constipation (2 patients) Gastrointestinal disorders (4 patients) Behaviour disorder (2 patients) Movements involuntary (1 patient) Drowsiness (1 patient) Skin rash (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/21310336/
40 mg multiple, oral Higher than recommended Dose: 40 mg Route: oral Route: multiple Dose: 40 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6741602/	unhealthy, 25 years Health Status: unhealthy Age Group: 25 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/6741602/	Other AEs: Dependence... Other AEs: Dependence (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/6741602/
5 mg 28 times / day multiple, oral Higher than recommended Dose: 5 mg, 28 times / day Route: oral Route: multiple Dose: 5 mg, 28 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6741602/	unhealthy, 35 years Health Status: unhealthy Age Group: 35 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/6741602/	Other AEs: Dependence... Other AEs: Dependence (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/6741602/
0.75 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 0.75 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.75 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17690057/	unhealthy, 4-15 years Health Status: unhealthy Age Group: 4-15 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17690057/	Disc. AE: Chorea, Rash... AEs leading to discontinuation/dose reduction: Chorea (1 patient) Rash (1 patient) Hyperactivity (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/17690057/
24 mg 1 times / day multiple, oral Highest studied dose Dose: 24 mg, 1 times / day Route: oral Route: multiple Dose: 24 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6136938/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/6136938/	Sources: https://pubmed.ncbi.nlm.nih.gov/6136938/
41 mg 1 times / day multiple, oral Highest studied dose Dose: 41 mg, 1 times / day Route: oral Route: multiple Dose: 41 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6136938/	unhealthy, children Health Status: unhealthy Age Group: children Sex: unknown Sources: https://pubmed.ncbi.nlm.nih.gov/6136938/	Sources: https://pubmed.ncbi.nlm.nih.gov/6136938/
8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3984771/	unhealthy, mean 49.7 years Health Status: unhealthy Age Group: mean 49.7 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3984771/	Other AEs: Extrapyramidal symptoms... Other AEs: Extrapyramidal symptoms (77%) Sources: https://pubmed.ncbi.nlm.nih.gov/3984771/

AEs

AE	Significance	Dose	Population
Drowsiness	1 patient Disc. AE	0.55 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 0.55 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.55 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21310336/	unhealthy, 1-18 years Health Status: unhealthy Age Group: 1-18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21310336/
Movements involuntary	1 patient Disc. AE	0.55 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 0.55 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.55 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21310336/	unhealthy, 1-18 years Health Status: unhealthy Age Group: 1-18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21310336/
Skin rash	1 patient Disc. AE	0.55 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 0.55 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.55 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21310336/	unhealthy, 1-18 years Health Status: unhealthy Age Group: 1-18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21310336/
Behaviour disorder	2 patients Disc. AE	0.55 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 0.55 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.55 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21310336/	unhealthy, 1-18 years Health Status: unhealthy Age Group: 1-18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21310336/
Constipation	2 patients Disc. AE	0.55 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 0.55 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.55 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21310336/	unhealthy, 1-18 years Health Status: unhealthy Age Group: 1-18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21310336/
Gastrointestinal disorders	4 patients Disc. AE	0.55 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 0.55 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.55 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21310336/	unhealthy, 1-18 years Health Status: unhealthy Age Group: 1-18 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21310336/
Dependence	1 patient	40 mg multiple, oral Higher than recommended Dose: 40 mg Route: oral Route: multiple Dose: 40 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6741602/	unhealthy, 25 years Health Status: unhealthy Age Group: 25 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/6741602/
Dependence	1 patient	5 mg 28 times / day multiple, oral Higher than recommended Dose: 5 mg, 28 times / day Route: oral Route: multiple Dose: 5 mg, 28 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6741602/	unhealthy, 35 years Health Status: unhealthy Age Group: 35 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/6741602/
Chorea	1 patient Disc. AE	0.75 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 0.75 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.75 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17690057/	unhealthy, 4-15 years Health Status: unhealthy Age Group: 4-15 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17690057/
Hyperactivity	1 patient Disc. AE	0.75 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 0.75 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.75 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17690057/	unhealthy, 4-15 years Health Status: unhealthy Age Group: 4-15 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17690057/
Rash	1 patient Disc. AE	0.75 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 0.75 mg/kg, 1 times / day Route: oral Route: multiple Dose: 0.75 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17690057/	unhealthy, 4-15 years Health Status: unhealthy Age Group: 4-15 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17690057/
Extrapyramidal symptoms	77%	8 mg 1 times / day multiple, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: multiple Dose: 8 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3984771/	unhealthy, mean 49.7 years Health Status: unhealthy Age Group: mean 49.7 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/3984771/

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY523868	https://www.001chemical.com/chem/144-11-6
3B Scientific (Wuhan) Corp	3B3-065679	http://www.3bsc.com/index/pro_info.php?id=104940
Aurora Fine Chemicals LLC	A12.862.769	http://online.aurorafinechemicals.com/info?ID=A12.862.769
Aurum Pharmatech LLC	H2264	http://www.Aurumpharmatech.com/Product/ProductDetails/H2264
BLD Pharm	BD41291	http://www.bldpharm.com/products/144-11-6.html
ChemMol	49416053	http://www.chemmol.com/chemmol/49416053.html
Chemspace	CSSS00020675549	https://chem-space.com/CSSS00020675549
eNovation Chemicals	D674824	https://www.enovationchem.com/ProductDetails.asp?ProductID=D674824
Hairui	HR141293	http://www.hairuichem.com/en/product/144-11-6.html
mcule	MCULE-6065307656	https://mcule.com/MCULE-6065307656/
Molcore	MC523868	https://www.molcore.com/product/144-11-6
MolPort	MolPort-001-783-510	https://www.molport.com/shop/molecule-link/MolPort-001-783-510
OChem	12132	http://www.ocheminc.com/index.php?act=psearch&pid=144T116
Parchem	30212	http://www.parchem.com/chemical-supplier-distributor/Trihexyphenidyl-020212.aspx
Smolecule	S520860	http://www.smolecule.com/products/s520860
THE BioTek	bt-261968	https://www.thebiotek.com/product/inhibitors/bt-261968
Vitas-M Laboratory	BBL024959	http://www.request.vitasmlab.biz/index.php?option=com_search_stk&Itemid=22&stk=BBL024959&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink

PubMed

Title	Date	PubMed
Anti-nicotinic properties of anticholinergic antiparkinson drugs.	1998-11	9877318
Risperidone-induced rabbit syndrome.	1998-09	9926106
Electromyography in cervical dystonia: changes after botulinum and trihexyphenidyl.	1998-09	9748032
Chronic haloperidol produces a time- and dose-related slowing of lick rhythm in rats: implications for rodent models of tardive dyskinesia and neuroleptic-induced parkinsonism.	1998-05	9631956
Antiparkinsonian drugs causing inappropriate antidiuretic hormone secretion.	1998-01	9452348
Trihexyphenidyl withdrawal encephalopathy.	1997-01	9005879
Anticholinergic overdose induced torsade de pointes successfully treated with verapamil.	1996-11	9057687
Trihexyphenidyl as a possible therapeutic option in clozapine-induced nocturnal enuresis.	1996-03	8732317
Positron emission tomography of reversible intellectual impairment induced by long-term anticholinergic therapy.	1995-09	8523038
[A 75-year-old man with parkinsonism and delirium].	1994-01	8192765
Memory and cognitive impairments in a case of long-term trihexyphenidyl abuse.	1993-03	8378414
Successful treatment of levodopa-induced myoclonus and levodopa withdrawal-induced neuroleptic malignant syndrome. A case report.	1988-06	3401861
[Parkinson's disease associated with trihexyphenidyl (THP) induced dysphonia plicae ventricularis].	1988-04	3214980
Dystonic reactions with metoclopramide: is there a risk population?	1987-06	3454349
Parkinson's disease and myasthenia gravis: adverse effect of trihexyphenidyl on neuromuscular transmission.	1987-05	3033545
Lithium-induced akathisia.	1987-02	3100511
Anticholinergic-induced chorea in the treatment of focal dystonia.	1987	3504259
Bradycardia due to trihexyphenidyl hydrochloride.	1986-10	3769769
[Trihexyphenidyl (THP)-induced respiratory dyskinesia].	1986-02	3698411
Pharmacological modification of DDT-induced tremor and hyperthermia in rats: distributional factors.	1986	3088650
Withdrawal of trihexyphenidyl.	1985-03	3984771
Trihexyphenidyl dependence.	1984-06	6741602
Intravenous lorazepam in neuroleptic-induced catatonia.	1983-12	6139391
Malignant neuroleptic syndrome due to haloperidol. (A case report).	1983-01	6864584
Sexual dysfunction in women using major tranquilizers.	1982-09	7146292
Catalepsy produced by long-acting neuroleptics, fluphenazine enanthate and fluphenazine decanoate, in mice.	1982	7200248
Akathisia: an overlooked, distressing, but treatable condition.	1981-09	7276921
Reversibility of long-term tardive dyskinesia associated with antiparkinsonian medication: a case report.	1981-08	6114643
Neuroleptic malignant syndrome.	1980-07	7387498
Extrapyramidal syndrome with sodium valproate.	1979-10-27	391328
Choreiform movements induced by anticholinergic therapy.	1979-05-19	470689
Death attributed to ventricular arrhythmia induced by thioridazine in combination with a single Contac C capsule.	1978-10-07	709472
Mood elevating effect of trihexyphenidyl and biperiden in individuals taking antipsychotic medication.	1977-05	852367
Anticholinergic exacerbation of phenothiazine-induced extrapyramidal syndrome.	1976-09	961932
Amodiaquine-induced involuntary movements.	1976-07-24	974497
Skeletal muscle necrosis following membrane-active drugs plus serotonin.	1976-05	6632
[Outcome of Parkinsonism after two years of levodopa plus R04-4602 (author's transl)].	1975-07-01	785578
Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease.	1974-04	4838913
Abnormal involuntary movements induced by anticholinergic therapy.	1974	4155220
Toxic liver injuries.	1973-08	4800729
Neuroleptics and neurologic reactions.	1973-03	4144147
Depot phenothiazine treatment in acute psychosis: a sequential comparative clinical study.	1973-01	4566388
An unusual response to chlorpromazine therapy.	1972-10	5077102
Benzhexol-induced blindness in Parkinson's disease.	1972-03-04	5013835
Benzhexol and side effects with long-acting fluphenazine therapy.	1972-01-29	4550377
Benzhexol-induced hallucinosis.	1971-03-06	5557919
Toxic psychosis induced by benzhexol hydrochloride.	1970-10-10	5506119
Reversal of central anticholinergic syndrome in man by physostigmine.	1968-11-25	5755090
Phenothiazines in early labour.	1967-02-11	6017500
Drug-induced extrapyramidal symptoms: their incidence and treatment.	1967-01	6016862

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Extrapyramidal Reaction 4 to 10 mg orally each day. The total daily dose is best tolerated when administered in 2 or three equally separated doses. Usual Adult Dose for Parkinson's Disease Initial: 1 mg/day; increase by 2 mg increments at intervals of 3 to 5 days Usual dose: 6 to 10 mg/day in 3 to 4 divided doses; doses of 12 to 15 mg/day may be required Drug-induced extrapyramidal symptoms: Initial: 1 mg/day; increase as necessary to usual range of 5 to 15 mg/day in 3 to 4 divided doses Use in combination with levodopa: Usual range: 3 to 6 mg/day in divided doses

Route of Administration: Oral

In Vitro Use Guide

Trihexyphenidyl 10, 50, and 100 umol/L depressed the maximal upstroke velocity (Vmax) and the action potential amplitude (APA) of SAP in guinea pig papillary muscles.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 06:53:49 GMT 2025` Edited by `admin` on `Wed Apr 02 06:53:49 GMT 2025`
Record UNII	6RC5V8B7PO
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TRIHEXYPHENIDYL

Official Name

English

APO-TRIHEX

Preferred Name

English

NSC-12268

Code

English

Trihexyphenidyl [WHO-DD]

Common Name

English

TRIHEXYPHENIDYL [VANDF]

Common Name

English

TRIHEXYPHENIDYL [HSDB]

Common Name

English

1-CYCLOHEXYL-1-PHENYL-3-(1-PIPERIDYL)PROPAN-1-OL

Systematic Name

English

trihexyphenidyl [INN]

Common Name

English

BENZHEXOL

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C38149